Fewer than 20% of commercial nanomaterials have been tested with ISO-harmonized toxicity protocols, so safety data sheets for most nanomaterials are based on bulk material data

When a manufacturer purchases nano-titanium dioxide, nano-zinc oxide, or nano-silica, the Safety Data Sheet (SDS) they receive almost certainly reports toxicity data derived from the bulk (micron-scale) form of the same chemical. Fewer than 20% of commercially used nanomaterials have been tested using harmonized ISO-aligned exposure and toxicity testing protocols specific to their nanoscale form. The SDS may list the same LD50, the same OEL, and the same hazard classifications as the bulk powder — even though decades of research have established that nanoscale materials can have radically different toxicity profiles due to their higher surface-area-to-volume ratio, different crystal structure, and ability to generate reactive oxygen species. The practical consequence falls on occupational health officers, lab safety managers, and environmental compliance teams who rely on SDS data to make risk management decisions. They are selecting PPE, designing ventilation systems, and setting internal exposure limits based on safety data that does not describe the material they are actually handling. A lab worker handling nano-TiO2 might be told the OEL is 10 mg/m3 (the bulk TiO2 PEL), when NIOSH recommends 0.3 mg/m3 for ultrafine TiO2 — a 33-fold difference. The worker thinks they are protected; they are not. This persists because the OECD Test Guidelines were designed for conventional chemicals and have been slow to adapt to particulate nanomaterials. Testing nanomaterials requires addressing dose metrics (mass vs. surface area vs. particle number), dispersion protocols (nanomaterials agglomerate in test media, changing effective dose), and interference with assay readouts (nanoparticles absorb light, bind proteins, and generate false signals in standard cytotoxicity assays). These are not trivial adaptations — they require fundamentally rethinking how toxicity testing is performed. The OECD Working Party on Manufactured Nanomaterials has been working on this since 2006, but as of 2025 many test guidelines still lack nano-specific annexes, and the reference nanomaterials needed for method validation remain scarce.